Fosfomycin: Difference between revisions
From IDWiki
(Created page with "== Background == === Mechanism of Action === * Inhibits an enzyme-catalyzed reaction in cell wall synthesis * Bacteridical === Spectrum of Activity === * Active against ma...") Â |
(→â€) |
||
| Line 1: | Line 1: | ||
| − | == |
+ | ==Background== |
| − | === |
+ | ===Mechanism of Action=== |
| − | * |
+ | *Inhibits an enzyme-catalyzed reaction in cell wall synthesis |
| − | * |
+ | *Bacteridical |
| − | === |
+ | ===Spectrum of Activity=== |
| − | * |
+ | *Active against many Gram-positive bacteria, including MSSA, MRSA, [[Staphylococcus epidermidis]], [[Streptococcus pneumoniae]], [[Enterococcus faecalis]], [[Enterococcus faecium]], and [[VRE]] |
| − | * |
+ | *Active against many Gram-negative bacteria, including regular [[Enterobacterales]], CRE, and ESBL |
| − | ** |
+ | **Unclear if effective against [[Pseudomonas]] |
| − | * |
+ | *Limited activity against gut anaerobes, but does cover [[Peptostreptococcus]] |
| − | === |
+ | ===PK/PD=== |
| − | * |
+ | *Efficacy predicted by time-above-MIC |
| − | == |
+ | === Breakpoints === |
| + | * Determined by agar (not broth) dilution |
||
| ⚫ | |||
| + | * [[Enterobacterales]]: susceptible if MIC ≤32, resistance if MIC >32 |
||
| ⚫ | |||
| + | * [[Pseudomonas aeruginosa]]: no MIC breakpoints; ECV is 128 mg/L |
||
| + | * [[Acinetobacter]]: no MIC breakpoints or ECV |
||
| − | == |
+ | ==Dosing== |
| ⚫ | |||
| − | === Monitoring === |
||
| ⚫ | |||
| + | ==Safety== |
||
| ⚫ | |||
| − | === |
+ | ===Monitoring=== |
| ⚫ | |||
| ⚫ | |||
| + | |||
| + | ===Pregnancy=== |
||
| + | |||
| ⚫ | |||
Revision as of 11:04, 26 August 2020
Background
Mechanism of Action
- Inhibits an enzyme-catalyzed reaction in cell wall synthesis
- Bacteridical
Spectrum of Activity
- Active against many Gram-positive bacteria, including MSSA, MRSA, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, and VRE
- Active against many Gram-negative bacteria, including regular Enterobacterales, CRE, and ESBL
- Unclear if effective against Pseudomonas
- Limited activity against gut anaerobes, but does cover Peptostreptococcus
PK/PD
- Efficacy predicted by time-above-MIC
Breakpoints
- Determined by agar (not broth) dilution
- Enterobacterales: susceptible if MIC ≤32, resistance if MIC >32
- Pseudomonas aeruginosa: no MIC breakpoints; ECV is 128 mg/L
- Acinetobacter: no MIC breakpoints or ECV
Dosing
- Uncomplicated UTI: fosfomycin 3 g PO once
- Complicated UTI: fosfomycin 3 g PO q72h for 2 to 3 doses
Safety
Monitoring
- Hypokalemia, high sodium content, dose-limiting nausea, vomiting, and diarrhea
Pregnancy
- Safe in pregnancy
